Loading stock data…
$161.49+5.17 (+3.31%)
Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States.
Axsome Therapeutics, Inc. in the Healthcare sector is trading at $161.49 with a market capitalization of $11.0B. Wall Street consensus targets $283.63 (22 analysts), implying a +75.6% move over the next 12 months. The stock is currently 38% below its 52-week high of $260.19, remaining 19.4% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: RSI 12 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $218.38M↑ | $191.20M↓ | $196.00M↑ | $170.99M↑ | $150.04M |
| Gross Profit | $204.81M↑ | $176.48M↓ | $183.67M↑ | $159.08M↑ | $136.59M |
| Operating Income | -$51.14M↑ | -$62.77M↓ | -$36.02M↓ | -$32.92M↑ | -$44.82M |
| Net Income | -$51.31M↑ | -$64.54M↓ | -$28.56M↑ | -$47.23M↑ | -$47.97M |
Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextrometho...